PHRX (Pharmagen) ROIC %: -23.88% (As of Mar. 2014)


What is Pharmagen ROIC %?

Pharmagen PHRX -90.00% ROIC % is -23.88% as of Mar. 2014.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Pharmagen's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2014 was -23.88%.

As of today (2026-06-28), Pharmagen's WACC % is 0.00%. Pharmagen's ROIC % is 0.00% (calculated using TTM income statement data). Pharmagen earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Pharmagen  (OTCPK:PHRX) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Pharmagen's WACC % is 0.00%. Pharmagen's ROIC % is 0.00% (calculated using TTM income statement data). Pharmagen earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Pharmagen ROIC % Related Terms


Pharmagen ROIC % Historical Data

* Premium members only.

The historical data trend for Pharmagen's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmagen ROIC % Chart

Pharmagen Annual Data
Trend Jun10 Jun11 Dec12 Dec13
ROIC %
-122.73 -78.41 -143.81 -44.35

Pharmagen Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.04 -25.64 -36.51 -40.52 -23.88

PHRX vs FZMD, SNYR, SGMFF: ROIC % Comparison

For the Medical Distribution subindustry, Pharmagen's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmagen ROIC % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Pharmagen's ROIC % distribution charts can be found below:

* The bar in red indicates where Pharmagen's ROIC % falls into.



Pharmagen ROIC % Calculation

Pharmagen's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2013 is calculated as:

ROIC % (A: Dec. 2013 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2012 ) + Invested Capital (A: Dec. 2013 ))/ count )
=-2.159 * ( 1 - 0% )/( (2.805 + 6.932)/ 2 )
=-2.159/4.8685
=-44.35 %

where

Pharmagen's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2014 is calculated as:

ROIC % (Q: Mar. 2014 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2013 ) + Invested Capital (Q: Mar. 2014 ))/ count )
=-1.644 * ( 1 - 0% )/( (6.932 + 6.839)/ 2 )
=-1.644/6.8855
=-23.88 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2014) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -23.88% mean?
Pharmagen (PHRX) has a ROIC % of -23.88% as of Mar. 2014. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Pharmagen and its competitors.
Is Pharmagen's ROIC % too high?
Pharmagen's current ROIC % is -23.88%.
How does Pharmagen's ROIC % compare to FZMD and SNYR?
Pharmagen's ROIC % of -23.88% can be compared against companies in the Medical Distribution industry. The industry median ROIC % is 5.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Medical Distribution company?
The median ROIC % among Medical Distribution companies is 5.32, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Pharmagen and its competitors. For the Medical Distribution industry, the median ROIC % is 5.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmagen's current ROIC % is -23.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagen stock overvalued right now?
Pharmagen (PHRX) has a current ROIC % of -23.88%. The current ROIC % is -23.88%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Pharmagen (PHRX), the current ROIC % is -23.88% as of Mar. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagen Business Description

Address 9337 Fraser Avenue, Silver Spring, MD, USA, 20910
Pharmagen Inc as a distributor of specialty drugs, compounding and admix pharmacy, and producer of over-the-counter branded multivitamins to the healthcare provider market. The company distributes hard-to-find and specialty drugs to the healthcare provider market throughout the United States, while functioning as an aggregator of real-time market demand for these products.